AcariaHealth is proud to dispense RHAPSIDO® (remibrutinib), a newly FDA-approved therapy for adults with chronic spontaneous urticaria (CSU) who remainsymptomatic despite H1 antihistamine treatment.

A New Era in CSU Care
CSU is a chronic condition marked by recurring hives and swelling without a known external trigger, significantly impacting patients' quality of life. For many patients, standard antihistamines aren’t enough, and until now, advanced options were limited to injectable biologics or off-label treatments.

As the first oral, targeted Bruton’s tyrosine kinase (BTK) inhibitor approved for CSU, RHAPSIDO offers a convenient, non-injectable alternative that directly targets immune cell signaling to help control symptoms at their source.

With twice-daily oral dosing and no requirement for routine lab monitoring, RHAPSIDO helps reduce treatment burden and improve accessibility, especially for patients who prefer to avoid injections or frequent clinic visits.

Seamless Pharmacy Support
As your specialty pharmacy partner, AcariaHealth is here to ensure a smooth experience for both patients and providers. Our services for RHAPSIDO include:

• Comprehensive benefits investigation and prior authorizations
• Quick, reliable medication delivery
• Personalized onboarding and education
• Ongoing adherence and side effect management

We work hand-in-hand with care teams to ensure every patient begins therapy promptly and receives ongoing support throughout treatment. Providers can contact AcariaHealth to connect with our clinical support team for more information or assistance.

Moving Forward with Confidence
The approval of RHAPSIDO marks a major milestone in CSU care, offering new hope for patients living with the burden of chronic hives and itching. At AcariaHealth, we’re committed to supporting this innovative therapy and the patients who benefit from it.

Learn More
For providers: rhapsido-hcp.com

For patients and families: rhapsido.com

Follow AcariaHealth on LinkedIn for the latest specialty pharmacy updates and clinical insights.